Dan Curtis joins Amylon Therapeutics as Chief Development Officer

Dan Curtis joins Amylon Therapeutics as Chief Development Officer Cambridge, Massachusetts, 26 June 2018 - Amylon Therapeutics, a biotechnology company using an ultragenetics approach towards neurological disorders, announces the appointment of Daniel Curtis PhD as...

Amylon Therapeutics and Alcyone Lifesciences enter into partnership

Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D Cambridge, Massachusetts, April 5, 2018 – Amylon...

Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics

Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics   LEIDEN, The Netherlands, February 21st 2018, Amylon Therapeutics, a biotechnology company using an ultra-genetic approach towards neurological disorders, announces the appointment of Bo Jesper Hansen...

ProQR spins out Amylon Therapeutics

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of...

Amylon Therapeutics rondt eerste fase startkapitaal af

Amylon Therapeutics rondt eerste fase startkapitaal af, Focus op aandoeningen van het centraal zenuwstelsel. Belangrijkste updates Amylon Therapeutics B.V. is een spin-off bedrijf van ProQR Therapeutics N.V., een aan NASDAQ genoteerd biofarmaceutisch bedrijf gevestigd...

Amylon Therapeutics announces seed investment round

Amylon Therapeutics announces seed investment round, focus on CNS disorders   Key updates Amylon Therapeutics B.V. is a spin-off company from ProQR Therapeutics N.V., a NASDAQ listed biopharmaceutical company based in Leiden, the Netherlands. Amylon announces the...

Follow us on social media